QAD Inc. (NASDAQ:QADA) (NASDAQ:QADB), a leading provider of enterprise software and services for global manufacturing companies, today announced Bimeda ®, a leading manufacturer, distributor and marketer of Animal Health products, selected QAD Enterprise Applications to support the company’s rapid growth and global acquisition strategy. Bimeda ®, with its headquarters in Dublin, Ireland, develops, manufactures, distributes and markets a wide range of veterinary products which are sold in all five continents and more than seventy-five countries worldwide. To date the company's main focus has been on high-quality products to treat and prevent disease and parasite infestation in livestock, poultry, horses and pets. Now the company is engaging in an aggressive growth strategy to align manufacturing operations worldwide. Bimeda ® Utilizes QAD ERP Life Science Edition QAD Enterprise Applications Life Science Edition helps enable Bimeda ® to meet the stringent regulations required of life science manufacturers. The Life Science Edition supports critical quality requirements, including regulatory compliance and Device History/Electronic Batch Record requirements as well as providing a set of tools to support validation of Current Good Manufacturing Practices (cGMP). QAD Enterprise Applications supports robust audit trails and eSignatures as mandated by regulators. “QAD provided excellent service throughout the entire process that supported the rapid deployment of the core model of QAD Enterprise Applications for our Dublin headquarters,” said Gary Doyle, Bimeda ® chief financial officer. “As a result of this project, we have reduced software customizations by 33%. We have successfully implemented QAD Enterprise Applications in all of our European and North America facilities and look forward to implementing a single version of QAD on its unique domain architecture across all of our global sites.” QAD Enterprise Applications delivers to Bimeda ® :
- Qualified ERP System with IQ’s and OQ’s
- Integrated Batch History Reporting
- Robust Cradle-to-Grave Lot Traceability
- Intuitive and Easy-to-Use Interface
- cGMP Validation Support and Tools
- Built-in Industry Best Practices and Processes
More than 400 life sciences manufacturing sites in more than 60 countries around the world have deployed QAD Enterprise Applications. Companies ranging from start-ups to multinationals enjoy the simplicity, reliability and performance that QAD delivers.For more information about QAD Enterprise Applications Life Sciences Edition, please visit: www.qad.com/erp/Life-Sciences/ About Bimeda ® Bimeda ® is a global manufacturer and marketer of a variety of novel and generic animal health pharmaceutical product dosage forms produced in seven manufacturing plants in Brazil, Canada, Ireland, Kenya, the UK and the USA. Additional information regarding Bimeda ® and their products is available by visiting www.bimeda.com. About QAD – The Effective Enterprise QAD Inc. (NASDAQ: QADA) (NASDAQ: QADB), is a leading provider of enterprise software and services designed for global manufacturing companies. For more than 30 years, QAD has provided global manufacturing companies with an enterprise resource planning (ERP) system that supports operational requirements; including financials, manufacturing, demand and supply chain planning, customer management, business intelligence and business process management. QAD offers flexible deployment options like QAD On Premise software and QAD On Demand software-as-a-service. Customers can operate in a blended environment where some users can be deployed On Premise and some users deployed via On Demand while offering the same end-user experience. With QAD, customers and partners in the automotive, consumer products, food and beverage, high technology, industrial products and life sciences industries can better align daily operations with their strategic goals to meet their vision of becoming more Effective Enterprises. For more information about QAD, telephone +1 805-566-6000, visit www.qad.com. “QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners. Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expects”, “believes”, “anticipates”, “could”, “will likely result”, “estimates”, “intends”, “may”, “projects”, “should”, and variations of these words and similar expressions are intended to identify these forward looking statements. Forward-looking statements are based on the company’s current expectations and assumptions regarding its business, the economy and future conditions. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to, evolving demand for the company's software products and products that operate with the company's products; the company's ability to sustain license and service demand; the company's ability to leverage changes in technology; the company's ability to sustain customer renewal rates at current levels; the publication of opinions by industry and financial analysts about the company, its products and technology; the reliability of estimates of transaction and integration costs and benefits; the entry of new competitors or new offerings by existing competitors and the associated announcement of new products and technological advances by them; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales as a result of lengthy sales cycles; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. In addition, revenue and earnings in the enterprise resource planning (ERP) software industry are subject to fluctuations. Software license revenue, in particular, is subject to variability with a significant proportion of revenue earned in the last month of each quarter. Given the high margins associated with license revenue, modest fluctuations can have a substantial impact on net income. Investors should not use any one quarter's results as a benchmark for future performance. For a more detailed description of the risk factors associated with the company and the industries in which it operates, please refer to the company's Annual Report on Form 10-K for fiscal 2013 ended January 31, 2013, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission.